José A Galván

6PUBLICATIONS
27CO-AUTHORS
Molecular targetsTumour immunologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 18, 2023
Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma.

L Paige Ferguson, Jovylyn Gatchalian, Matthew L McDermott

|Nov 17, 2022
Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion.

Qiqun Zeng, Sadegh Saghafinia, Agnieszka Chryplewicz

|Aug 27, 2021
LAG-3 Expression Predicts Outcome in Stage II Colon Cancer.

Gaëlle Rhyner Agocs, Naziheh Assarzadegan, Richard Kirsch

|Jun 18, 2020
A new aggressive xenograft model of human colon cancer using cancer-associated fibroblasts.

Ester Fernando-Macías, Maria Teresa Fernández-García, Eva García-Pérez

|Dec 13, 2019
Immunohistochemical analysis of the expression of cancer-associated fibroblast markers in esophageal cancer with and without neoadjuvant therapy.

José A Galván, Julia Wiprächtiger, Julia Slotta-Huspenina

|Nov 30, 2018
Evaluation of Radiolabeled Girentuximab In Vitro and In Vivo.

Tais Basaco, Stefanie Pektor, Josue M Bermudez

Pageof 1

Frequent Collaborators

1 joint publications

Manfred Heller

1 joint publications

Matthias Miederer

1 joint publications

Luis Barneo-Serra

1 joint publications

Qiqun Zeng